euro adhoc: Intercell AG / Annual Reports / Intercell presents 2006 Annual Report

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

annual report

27.04.2007

Following a successful year, Intercell AG (VSE, "ICLL") today
presents its Annual Report 2006.

The illustrated Annual Report contains the audited consolidated
financial statements according to IFRS and gives detailed information
on Intercell’s latest achievements and anticipated milestones. It
highlights the company’s progress in product development and the
scientific and commercial potential of its technology platforms. At
the same time, Intercell AG publishes its statutory financial report
according to Austrian GAAP.

The online version of the Annual Report is now available for download
at www.intercell.com. A hard copy can be requested at Intercell’s
Communication Department by mail(communications@intercell.com) or by
phone (+43-1-20620-0).

About Intercell AG:

Intercell AG is a growing biotechnology company which focuses on the
design and Intercell AG is a growing biotechnology company which
focuses on the design and development of novel vaccines for the
prevention and treatment of infectious diseases with substantial
unmet medical need. The Company develops antigens and adjuvants which
are derived from its proprietary technology platforms, and has
in-house GMP manufacturing capability. Based on these technologies,
Intercell has strategic partnerships with a number of global
pharmaceutical companies, including Novartis, Merck&Co., Wyeth,
sanofi pasteur, Kirin and the Statens Serum Institut. The Company’s
leading product, a prophylactic vaccine against Japanese
Encephalitis, successfully concluded pivotal Phase III clinical
trials in 2006. The regulatory process towards a Biologics License
Application (BLA) to the U.S. Food and Drug Administration (FDA) has
been initiated. The broad development pipeline includes a Pseudomonas
vaccine in Phase II, a therapeutic vaccine for Hepatitis C in Phase
II, partnered vaccines for Tuberculosis and S.aureus which are in
Phase I, and five products focused on infectious diseases in
preclinical development. Intercell is listed on the Vienna stock
exchange under the symbol "ICLL".

For more information please visit: www.intercell.com

end of announcement euro adhoc 27.04.2007 08:13:24
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market